Skip to main content

imnn-001

Generic: PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector IMNN-001

imnn-001: 3 clinical trials tracked.

imnn-001 evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about imnn-001, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 1 study sponsors
Clinical Trial Registry Records (3)

A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

NCT06915025Registry updated 2026-10-05·Phase 3·IMNN
Recruiting

Primary endpoint: Overall Survival

InterventionalRandomizedopen500 targetStarted 2025-07Completion 2032-109 sites · United StatesImunon

Phase II Study Evaluating the Effect of IMNN-001 on Second Look Laparoscopy (SLL) in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT05739981Registry updated 2026-10-05·Phase 1/Phase 2·IMNN
Recruiting

Primary endpoint: Minimal Residual Disease

InterventionalRandomizedopen30 targetStarted 2023-02Completion 2028-084 sites · United StatesImunon

A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT03393884Registry updated 2026-05-04·Phase 1/Phase 2·IMNN
Active, not recruiting

Primary endpoint: PFS

InterventionalRandomizedopen130 targetStarted 2018-09Completion 2026-0521 sites · Canada, United StatesImunon